On November 1, 2022 Veracyte, Inc. (Nasdaq: VCYT) reported that three abstracts highlighting the company’s unique, multi-omics immuno-oncology capabilities and offerings will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 37th Annual Meeting & Pre-Conference Programs (SITC 2022), taking place November 8-12, 2022, in Boston (Press release, Veracyte, NOV 1, 2022, View Source [SID1234622700]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our comprehensive multi-omics expertise and tools have demonstrated potential to address critical questions related to the newest areas of cancer therapy, including which patients are most likely to benefit from immunotherapies," said Corinne Danan, general manager for Veracyte’s Biopharma business unit. "The abstracts being presented at SITC (Free SITC Whitepaper) 2022 will provide additional insight into how our Veracyte Biopharma Atlas and Brightplex offerings can enhance understanding of the tumor microenvironment to help our biopharma partners confidently advance every step of their oncology drug development programs."
Following are details of the Veracyte abstracts that will be shared during poster sessions at the SITC (Free SITC Whitepaper) 2022 Annual Meeting. Poster sessions will be held in the Boston Convention and Exhibition Center, Hall C.
Veracyte will also host a symposium at SITC (Free SITC Whitepaper) 2022 to provide additional detail regarding the development of the DLBCL Biopharma Atlas featured in poster 1454. The company’s Biopharma Atlas, generated through unsupervised multi-omics and multimodal assessment of thousands of parameters, may be used to generate customized maps and clusters for patient group identification and clinical outcome interpretation.
About Veracyte’s Biopharma Offerings
Veracyte collaborates with biopharma partners to provide novel insights, expertise and capabilities that empower partners to confidently advance every step of their oncology drug development programs. With an array of offerings that include the Veracyte Biopharma Atlas, Brightplex and Decipher GRID Real World Data (RWD), Veracyte helps address each partner’s unique oncology drug development needs, including therapeutics and diagnostic development, clinical development insights and decisions, clinical trial patient selection, and clinical trial management. For more information, please visit View Source